Based on 2 publication(s) in Google Scholar
Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 252917-06-9
- Fòrmula: C22H18Cl2N8
- Peso molecular:465.34
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Laduviglusib (GMP)
More
Actividad biológica
|
GSK-3β 6.7 nM (IC50) |
GSK-3α 10 nM (IC50) |
CDC2 8800 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
0.13 μM
Compound: 1
|
Inhibition of GSK3 in CHO cells expressing insulin receptor assessed as activation of glycogen synthase measured after 30 mins in presence of glucose-6-phosphate by filter paper assay
Inhibition of GSK3 in CHO cells expressing insulin receptor assessed as activation of glycogen synthase measured after 30 mins in presence of glucose-6-phosphate by filter paper assay
|
[PMID: 31926786] |
| HepG2 | EC50 |
1.5 μM
Compound: 1, CHIR-99021
|
Inhibition of GSK3-beta in human HepG2 cells assessed as incorporation of [3H]glucose into glycogen after 3 hrs by liquid scintillation counting
Inhibition of GSK3-beta in human HepG2 cells assessed as incorporation of [3H]glucose into glycogen after 3 hrs by liquid scintillation counting
|
[PMID: 22261023] |
Laduviglusib (GMP) (20 μM, 21 days) transdifferentiates mouse fibroblasts to neurons (determined by increased number of TAUEGFP-/TUJ1-positive neuronal cells)[1].
Laduviglusib (GMP) (3-5 μM, 2 days) induces somatic cells differentiation of pluripotent stem (PS) cells (the detailed method refers to the reference)[2].
Laduviglusib (GMP) (12 μM, 5 days) converts human fibroblasts (HFF) into functional cardiomyocytes[3].
Laduviglusib (GMP) (3 μM, 4 days, hESCs) activates the canonical WNT signaling pathway, confirmed by β-catenin translocation into the nucleus[4].
Laduviglusib (GMP) (in MEFs expressing MyoD) enhances the marked increase in the number of proliferative cells led by RepSox (GMP) (HY-13012G) together with Forskolin (HY-15371)[5].
Laduviglusib (GMP) (5 μM, 1 day) can be used to generate islets (hCiPSC-islets) from human chemically induced pluripotent stem cells (hCiPSC)[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 252917-06-9
-
Appearance Solid
-
Peso molecular 465.34
-
Fòrmula C22H18Cl2N8
-
Color White to off-white
-
SMILES
N#CC1=CC=C(N=C1)NCCNC2=NC=C(C(C3=CC=C(Cl)C=C3Cl)=N2)C4=NC=C(N4)C
-
Synonyms
CHIR-99021 (GMP); CT99021 (GMP)
-
Envío
Shipping with dry ice.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Antioxidants (Basel)
Alpha-Lipoic Acid Inhibits IFN-γ-Induced PD-L1 Expression in Prostate Cancer Cells and Enhances T-Cell-Mediated Anti-Tumor Cytotoxicity. [Abstract]2026 Mar 25;15(4):413. PMID: 42072056 -
Solvente y solubilidad
DMSO : 4.55 mg/mL (9.78 mM; warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Li X, et al. Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons. Cell Stem Cell. 2015;17(2):195-203. [Content Brief]
[2]. Guan J et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022;605(7909):325-331. [Content Brief]
[3]. Cao N, et al. Conversion of human fibroblasts into functional cardiomyocytes by small molecules. Science. 2016;352(6290):1216-1220. [Content Brief]
[4]. Choi IY, et al. Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. Cell Rep. 2016;15(10):2301-2312. [Content Brief]
[5]. Bar-Nur O, et al. Direct Reprogramming of Mouse Fibroblasts into Functional Skeletal Muscle Progenitors. Stem Cell Reports. 2018 May 8;10(5):1505-1521. [Content Brief]
[6]. Zhao J, et al. Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates. Nat Med. 2022 Feb;28(2):272-282. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1490 mL | 10.7448 mL | 21.4897 mL | 53.7242 mL |
| 5 mM | 0.4298 mL | 2.1490 mL | 4.2979 mL | 10.7448 mL |
Laduviglusib (GMP) Related Classifications
HY-10182G Related Classifications
Powered by Bioz